These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22565063)

  • 1. Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
    Peer CJ; McManus TJ; Hurwitz HI; Petros WP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jun; 898():32-7. PubMed ID: 22565063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry.
    Liu K; Zhong D; Zou H; Chen X
    J Pharm Biomed Anal; 2010 Aug; 52(4):550-6. PubMed ID: 20138454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy.
    Shiraiwa K; Suzuki Y; Uchida H; Iwashita Y; Tanaka R; Iwao M; Tada K; Hirashita T; Masuda T; Endo Y; Inomata M; Itoh H
    Sci Rep; 2021 Feb; 11(1):3132. PubMed ID: 33542452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitive MS/MS-liquid chromatography assay for simultaneous determination of tegafur, 5-fluorouracil and 5-fluorodihydrouracil in plasma.
    Remaud G; Boisdron-Celle M; Morel A; Gamelin A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Sep; 824(1-2):153-60. PubMed ID: 16061432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
    Büchel B; Rhyn P; Schürch S; Bühr C; Amstutz U; Largiadèr CR
    Biomed Chromatogr; 2013 Jan; 27(1):7-16. PubMed ID: 22454320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
    Etienne-Grimaldi MC; Cardot JM; François E; Renée N; Douillard JY; Gamelin E; Milano G
    Clin Pharmacol Ther; 2008 Mar; 83(3):413-5. PubMed ID: 17637782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
    Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
    Kamiya O; Hoshino A; Ohara K; Nagata K; Kojima T; Sugihara T; Yamada M; Suzuki M; Kimura K; Fujii S
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2565-72. PubMed ID: 6418079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT].
    Takahashi N; Nitta A; Saitou T; Mori Y; Kunii Y; Kikuchi K
    Gan To Kagaku Ryoho; 1988 Aug; 15(8):2319-23. PubMed ID: 3136701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
    Pazdur R
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):35-9. PubMed ID: 9348565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
    Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
    J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Level of 5-FU in cancerous and normal tissues of nude mice after oral administration of tegafur coadministered with uracil (UFT)].
    Sekiguchi I; Suzuki M; Tamada T; Nishida M
    Gan To Kagaku Ryoho; 1985 May; 12(5):1094-8. PubMed ID: 3922312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT].
    Maruyama M; Ebuchi M; Nagahama T; Takashima I; Hasegawa K; Ochiai T; Natui S
    Gan To Kagaku Ryoho; 2002 Nov; 29(12):2109-11. PubMed ID: 12484014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on the concentrations of 5-fluorouracil (5-FU), tegafur (ET) and uracil in bile: comparison of UFT or FT].
    Tomita T; Tajima T; Ishibashi M; Tagaya N; Aoki H; Itoh S; Kadowaki A; Kogure H; Tajima Y
    Gan To Kagaku Ryoho; 1989 Dec; 16(12):3755-62. PubMed ID: 2512859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
    Etienne-Grimaldi MC; François E; Cardot JM; Renée N; Douillard JY; Gamelin E; Bennouna J; Château Y; Milano G
    Clin Pharmacokinet; 2007; 46(11):953-63. PubMed ID: 17922560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
    Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
    J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.
    Ho DH; Covington W; Brown N; Lin SN; Pazdur R; Huo YY; Creaven PJ; Rustum YM; Meropol NJ; Lassere Y; Kuritani J; Hayakawa T
    Cancer Chemother Pharmacol; 2000; 46(5):351-6. PubMed ID: 11127938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.